½ÃÀ庸°í¼­
»óǰÄÚµå
1594481

½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå : Á¦Ç°, Ä¡·á ¿ëµµ, ÃÖÁ¾ ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Neurothrombectomy Devices Market by Product, Therapeutic Application (Arteriovenous Malformations & AV Fistulas, Cerebral Aneurysms, Cerebral Artery Stenosis), End-Use - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 199 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀåÀº 2023³â¿¡ 7¾ï 8,001¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 8¾ï 7,500¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 12.66%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 17¾ï 9,713¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½Å°æÇ÷ÀüÁ¦°Å±â´Â ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Ä¡·á¿¡ ÇʼöÀûÀÎ Àåºñ·Î, ³úµ¿¸Æ¿¡¼­ Ç÷ÀüÀ» ¹°¸®ÀûÀ¸·Î Á¦°ÅÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. °í·ÉÈ­¿Í ´ç´¢, °íÇ÷¾Ð µî »ýȰ½À°üº´ Áõ°¡·Î Àü ¼¼°è¿¡¼­ ³úÁ¹Áß ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ±× Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. ±× ¿ëµµ´Â º´¿ø, ½Å°æ°ú Àü¹® Ŭ¸®´Ð°ú °°Àº ÀÇ·á ½Ã¼³¿¡ Àû¿ëµÇ¸ç, ÃÖÁ¾»ç¿ëÀÚ´Â ½Å°æÇÐ ¹× ÁßÀçÀû ¿µ»óÀÇÇÐÀ» Àü¹®À¸·Î ÇÏ´Â ÀÇ·áÁøÀÔ´Ï´Ù. ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î Á¤È®µµ¿Í ¾ÈÀü¼ºÀ» ³ôÀÎ Â÷¼¼´ë ¸®Æ®¸®¹ö ¹× ÈíÀÔ Àåºñ °³¹ß µî ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÃÖ±Ù¿¡´Â ³úÁ¹Áß °ü¸®¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø Áõ°¡¿Í À¯¸®ÇÑ »óȯ Á¤Ã¥ÀÌ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±×·¯³ª ƯÈ÷ ½ÅÈï ±¹°¡ ½ÃÀå¿¡¼­´Â Àåºñ¿Í ½Ã¼úÀÇ ³ôÀº ºñ¿ë°ú À̸¦ Á¶ÀÛÇÒ ¼ö ÀÖ´Â ¼÷·ÃµÈ Àü¹®°¡°¡ ºÎÁ·ÇÏ´Ù´Â Á¡ÀÌ ½ÃÀåÀ» ¾ïÁ¦ÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» °³¹ßÇÏ¿© ¾Æ½Ã¾Æ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹Ì°³Ã´ ½ÃÀåÀ¸·ÎÀÇ ÁøÃâÀ» È®´ëÇÒ ¼ö ÀÖ´Â ±âȸ°¡ ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ Çõ½ÅÀº Á¶ÀÛ¼ºÀ» Çâ»ó½ÃŰ´Â ¼ÒÇüÈ­ Àåºñ¿Í ½Å¼ÓÇϰí Á¤È®ÇÑ Ç÷Àü Á¦°Å¸¦ Áö¿øÇÏ´Â AI ±â¹Ý Áø´Ü ¹× ¼ö¼ú Åø °³¹ß¿¡ ÃÊÁ¡À» ¸ÂÃâ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå Âü¿©ÀÚµéÀº ¶ÇÇÑ ÀÓ»óÀǸ¦ À§ÇÑ ±³À° ÇÁ·Î±×·¥À» °­È­Çϱâ À§ÇØ Á¤ºÎ ±â°ü ¹× ÀÇ·á ±â°ü°úÀÇ Çù·Âµµ °í·ÁÇØ¾ß ÇÕ´Ï´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í ¾à¸®ÇÐÀû Ç÷Àü ¿ëÇØ ¿ä¹ý°ú °°Àº ´ëü¿ä¹ý°úÀÇ °æÀï°ú ¾ö°ÝÇÑ ±ÔÁ¦ Á¤Ã¥Àº Áö¼ÓÀûÀÎ °úÁ¦ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ µµÀü¿¡µµ ºÒ±¸ÇÏ°í ½Å°æÇ÷ÀüÁ¦°Å¼ú ½ÃÀåÀº Áö¼ÓÀûÀÎ R&D ÅõÀÚ¿Í Àü·«Àû ÆÄÆ®³Ê½Ê¿¡ ÈûÀÔ¾î »ó´çÇÑ ¼ºÀåÀÌ ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. Çõ½Å°¡µéÀº ±â±âÀÇ È¿°ú¿Í ȯÀÚ °á°ú¸¦ °³¼±ÇÏ´Â µ¥ ÁýÁßÇØ¾ß Çϸç, ³ª³ëÅ×Å©³î·¯Áö°ú ¹ÙÀÌ¿À¼¾¼­ÀÇ ÅëÇÕÀ» ¸ð»öÇÒ ¼öµµ ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ½ÃÀåÀº ¿ªµ¿ÀûÀ̸ç, ³úÁ¹Áß Ä¡·á ¹× ÁßÀç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ±â¼ú Çõ½Å°ú Àü·«Àû È®ÀåÀÇ ¿©Áö°¡ Å®´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023³â] 7¾ï 8,001¸¸ ´Þ·¯
¿¹Ãø³â[2024³â] 8¾ï 7,500¸¸ ´Þ·¯
¿¹Ãø³â[2030³â] 17¾ï 9,713¸¸ ´Þ·¯
CAGR(%) 12.66%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÕ´Ï´Ù.

½Å°æÇ÷ÀüÁ¦°ÅÀåºñ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î ÀÎÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è¿¡¼­ ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áõ°¡
    • ³úÁ¹Áß ¿¹¹æÀ» À§ÇÑ ¼¼°è °¢±¹ Á¤ºÎÀÇ ±¸»ó
    • ½Å°æÇ÷ÀüÁ¦°Å¼ú¿¡ ´ëÇÑ »ç¶÷µéÀÇ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¾ö°ÝÇÏ°í º¹ÀâÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
  • ½ÃÀå ±âȸ
    • ÷´Ü ½Å°æÇ÷Àü Á¦°Å Àåºñ °³¹ß È®´ë
    • ½ÃÀå ÁøÃâ±â¾÷ÀÇ ÅõÀÚ Áõ°¡ ¹× »óȯ Á¤Ã¥ÀÇ ÀÌ¿ë °¡´É¼º
  • ½ÃÀå °úÁ¦
    • ½Å°æÇ÷ÀüÁ¦°Å±â¿Í °ü·ÃµÈ À§Ç輺

Porter's Five Forces: ½Å°æÇ÷Àü Á¦°Å Àåºñ ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« Åø

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½Å°æÇ÷ÀüÁ¦°Å±â ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ ÅøÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ¸ð»öÇϱâ À§ÇÑ ¸íÈ®ÇÑ ¹æ¹ýÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» º¸¿ÏÇϸç ÀáÀçÀû µµÀüÀ» ÇÇÇÔÀ¸·Î½á º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ½Å°æÇ÷ÀüÁ¦°Å±â ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ´ã°í ÀÖÀ¸¸ç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀ̰í Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ½Å°æÇ÷ÀüÁ¦°Å±â ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ¼¼ºÐÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÏ¿© °ø±Þ¾÷ü°¡ Ä¡¿­ÇÑ °æÀï¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º: ½Å°æÇ÷ÀüÁ¦°Å±â ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ½Å°æÇ÷ÀüÁ¦°Å±â ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ: ½Å°æÇ÷ÀüÁ¦°Å±â ½ÃÀå¿¡¼­ ¼º°øÀ¸·Î °¡´Â ±æ Â÷Æ®

½Å°æÇ÷ÀüÁ¦°Å±â ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÎ¹®¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ±â¼úÇϰí ÀÖ½À´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå : Á¦Ç°º°

  • ¼­·Ð
  • ÈíÀÎ ±â±â
  • Clot Retrievers
  • Ç÷°ü ½º³×¾î

Á¦7Àå ½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå : Ä¡·á ¿ëµµº°

  • ¼­·Ð
  • µ¿Á¤¸Æ ±âÇü(AVM)°ú AV ´©°ø
  • ³úµ¿¸Æ·ù
  • ³úµ¿¸ÆÇùÂøÁõ
  • ÇãÇ÷¼º ³úÁ¹Áß

Á¦8Àå ½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • ¼­·Ð
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±¸±Þ Ŭ¸®´Ð
  • º´¿ø

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå

  • ¼­·Ð
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå

  • ¼­·Ð
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå

  • ¼­·Ð
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

¾ð±ÞµÈ ±â¾÷

  • Abbott Laboratories
  • Acandis GmbH
  • Argon Medical Devices, Inc.
  • Boston Scientific Corporation
  • Edwards Lifesciences Corporation
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips N.V.
  • Medtronic Plc
  • NeuroVasc Technologies, Inc.
  • Penumbra, Inc.
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
  • Vesalio, LLC
KSA 24.11.29

The Neurothrombectomy Devices Market was valued at USD 780.01 million in 2023, expected to reach USD 875.00 million in 2024, and is projected to grow at a CAGR of 12.66%, to USD 1,797.13 million by 2030.

Neurothrombectomy devices are integral in the treatment of acute ischemic strokes, employed to physically remove blood clots from cerebral arteries. The necessity of these devices is underscored by the rising incidence of strokes globally, coupled with an aging population and increasing prevalence of lifestyle diseases like diabetes and hypertension. Their application spans healthcare facilities such as hospitals and specialty neurology clinics, with end-users being healthcare professionals specializing in neurology and interventional radiology. Market growth is primarily driven by advancements in technology, including the development of next-generation retrievers and aspiration devices that offer increased precision and safety. Recently, increasing government support for stroke management, alongside favorable reimbursement policies, presents lucrative opportunities. However, market constraints include the high cost of devices and procedures, coupled with a dearth of skilled professionals to operate them, especially in developing regions. Opportunities lie in developing cost-effective solutions and expanding reach to untapped markets in Asia and Africa. Innovations in the field may focus on miniaturization of devices for enhanced maneuverability and development of AI-powered diagnostic and surgical tools to support swift and precise clot removal. Market players should also consider collaboration with government bodies and health organizations to enhance training programs for clinicians. Nonetheless, stringent regulatory policies pose ongoing challenges, alongside the competition from alternative therapies like pharmacological thrombolysis. Despite these challenges, the neurothrombectomy market is expected to witness substantial growth, fueled by continuous R&D investments and strategic partnerships. Innovators should focus on improving device efficacy and patient outcomes, potentially exploring the integration of nanotechnology and biosensor advancements. Overall, the market is dynamic, with substantial scope for innovation and strategic expansion to cater to the growing demand for improved stroke treatments and interventions.

KEY MARKET STATISTICS
Base Year [2023] USD 780.01 million
Estimated Year [2024] USD 875.00 million
Forecast Year [2030] USD 1,797.13 million
CAGR (%) 12.66%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neurothrombectomy Devices Market

The Neurothrombectomy Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of acute ischemic stroke globally
    • Initiatives by government worldwide for the prevention of stroke
    • Growing awareness about the neurothrombectomy among the population
  • Market Restraints
    • Stringent and complex regulatory framework
  • Market Opportunities
    • Growing development of advanced neurothrombectomy devices
    • Increasing investments by market players and availability of reimbursement policies
  • Market Challenges
    • Risks associated with the neurothrombectomy devices

Porter's Five Forces: A Strategic Tool for Navigating the Neurothrombectomy Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neurothrombectomy Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neurothrombectomy Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neurothrombectomy Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neurothrombectomy Devices Market

A detailed market share analysis in the Neurothrombectomy Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neurothrombectomy Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neurothrombectomy Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neurothrombectomy Devices Market

A strategic analysis of the Neurothrombectomy Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neurothrombectomy Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Acandis GmbH, Argon Medical Devices, Inc., Boston Scientific Corporation, Edwards Lifesciences Corporation, Johnson & Johnson Services, Inc., Koninklijke Philips N.V., Medtronic Plc, NeuroVasc Technologies, Inc., Penumbra, Inc., Stryker Corporation, Teleflex Incorporated, Terumo Corporation, and Vesalio, LLC.

Market Segmentation & Coverage

This research report categorizes the Neurothrombectomy Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Aspiration/Suction Devices, Clot Retrievers, and Vascular Snares.
  • Based on Therapeutic Application, market is studied across Arteriovenous Malformations (AVMs) & AV Fistulas, Cerebral Aneurysms, Cerebral Artery Stenosis, and Ischemic Stroke.
  • Based on End-Use, market is studied across Ambulatory Surgical Centers, Emergency Clinics, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of acute ischemic stroke globally
      • 5.1.1.2. Initiatives by government worldwide for the prevention of stroke
      • 5.1.1.3. Growing awareness about the neurothrombectomy among the population
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent and complex regulatory framework
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing development of advanced neurothrombectomy devices
      • 5.1.3.2. Increasing investments by market players and availability of reimbursement policies
    • 5.1.4. Challenges
      • 5.1.4.1. Risks associated with the neurothrombectomy devices
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neurothrombectomy Devices Market, by Product

  • 6.1. Introduction
  • 6.2. Aspiration/Suction Devices
  • 6.3. Clot Retrievers
  • 6.4. Vascular Snares

7. Neurothrombectomy Devices Market, by Therapeutic Application

  • 7.1. Introduction
  • 7.2. Arteriovenous Malformations (AVMs) & AV Fistulas
  • 7.3. Cerebral Aneurysms
  • 7.4. Cerebral Artery Stenosis
  • 7.5. Ischemic Stroke

8. Neurothrombectomy Devices Market, by End-Use

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Emergency Clinics
  • 8.4. Hospitals

9. Americas Neurothrombectomy Devices Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Neurothrombectomy Devices Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Neurothrombectomy Devices Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Acandis GmbH
  • 3. Argon Medical Devices, Inc.
  • 4. Boston Scientific Corporation
  • 5. Edwards Lifesciences Corporation
  • 6. Johnson & Johnson Services, Inc.
  • 7. Koninklijke Philips N.V.
  • 8. Medtronic Plc
  • 9. NeuroVasc Technologies, Inc.
  • 10. Penumbra, Inc.
  • 11. Stryker Corporation
  • 12. Teleflex Incorporated
  • 13. Terumo Corporation
  • 14. Vesalio, LLC
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦